about
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus.Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?Prevalence of metabolic syndrome in rural and urban Chinese population in Qingdao.
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
What have we learned from the current trials?
@ast
What have we learned from the current trials?
@en
type
label
What have we learned from the current trials?
@ast
What have we learned from the current trials?
@en
prefLabel
What have we learned from the current trials?
@ast
What have we learned from the current trials?
@en
P1476
What have we learned from the current trials?
@en
P2093
George L Bakris
P304
P356
10.1016/S0025-7125(03)00129-9
P577
2004-01-01T00:00:00Z